Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare expanded disability status scale, annualized relapse
rate, Gad-enhanced brain lesions, and side effects after administration of rituximab and
glatiramer acetate among patients with active secondary progressive multiple sclerosis during
a one year follow up through a randomized clinical trial.